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Purpose. We investigated the incidence and extent of stent migration after endovascular sealing of 
abdominal aortic aneurysms (EVAS), its relationship with adherence to the instructions for use of the 
Nellix endograft and its association with aneurysm growth.  
 
Methods. In this retrospective single centre study, the clinical data and follow-up CT images of 
patients undergoing infra-renal EVAS with a minimum follow-up of 1 year were reviewed. The first 
postoperative CT scan at one month and the subsequent scans were used to measure the distances 
between the proximal end of the stent and reference visceral vessels using a previously validated 
technique. Device migration was based on the Society of Vascular Surgery definition of >10mm 
downward movement of either Nellix stent in the proximal landing zone; furthermore, we defined 
proximal displacement a downward movement of ≥4mm. Patients were categorised according to 
adherence to the old (2013) or new (2016) Nellix IFU. Aneurysm diameter was measured for each 
scan and a change of ≥5mm was deemed indicative of aneurysm growth.  
 
Results. Seventy-five patients were eligible for inclusion in our study. Over a 4-year period, migration 
≥4mm occurred in 42 (56%) patients and migration of ≥10mm in 16 (21%), with similar incidence in 
right and left stents. Migration ≥4mm was significantly more frequent among patients whose 
anatomy did not conform to any IFU (p=0.025). Presence of aneurysm growth ≥5mm was observed 
in 14 patients (19%) and was significantly associated with proximal displacement ≥4mm (p=0.03).  
 
Conclusion. Infra-renal EVAS may be complicated by proximal displacement and migration, 
particularly when performed outside IFU. The definition of migration used for EVAR is inappropriate 
for EVAS; a new consensus on definition and measurement technique is necessary. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Endovascular aneurysm sealing (EVAS) performed with the Nellix® endoprosthesis (Endologix Inc., 
Irvine, California, USA) received Conformité Européenne marking in April 2013 and was only recently 
introduced in clinical practice.1,2,3 Long term follow-up data is limited, however, type Ia, type Ib, and 
type II endoleaks have been reported in multiple studies.4,5,6,7,8 Migration has also been described in 
recent literature.6,7,8,9,10 Early outcomes dictated a change in the instructions for use (IFU) in October 
2016, with modifications aimed at reducing the occurrence of migration. The aim of this study was 
to establish the incidence of stent movement and migration after infra-renal EVAS, its relationship 
with adherence to IFU and its consequences.  
 
Methods 
This project falls within a programme of studies evaluating EVAS at our institution, therefore, formal 
ethical approval was not required; the study was registered as a service review. 
 
Study design and Inclusion criteria 
This was a retrospective, single centre, observational study on patients treated with infra-renal 
EVAS.  For inclusion, all patients were required to have had a baseline postoperative CT scan at 1 
month (≤6 weeks after device implantation) and at least 1 additional CT scan (minimum of 
12 months from the initial implantation procedure) available in the Digital Imaging and 
Communication in Medicine (National Electrical Manufacturers Association, Rosslyn, Va, USA) 
format. Our study excluded: patients in whom CT images were not available, patients undergoing 
EVAS extending into the supra-renal segment (with chimneys), patients undergoing EVAS as a 
secondary intervention (after previous aortic aneurysm surgery) and patients treated for ruptured 
aneurysms. 
 
Outcome measures and Definitions 
The outcome measure of the study was the incidence of migration as well as its relationship with 
adherence to IFU and aneurysm growth. The reporting standards of the Society for Vascular Surgery 
(SVS) define device migration as movement of >10 mm relative to anatomical landmarks or any 
migration leading to symptoms or requiring therapy.11 England et al specifically defined stent 
migration for the EVAS device in a recent study as ≥4mm relative to a vascular landmark.12 This cut-
off has also been used to define migration in fenestrated endovascular grafts.13 Our method 
included assessing and reporting stent graft movement (≥4 mm), which we defined as proximal 
displacement in this manuscript, and migration (>10mm), as defined by the SVS. The instructions for 
use (IFU) of the Nellix device changed in October 2016, when more restrictive anatomical criteria 
were introduced.14 We assessed if the aortic anatomy of the patients was within or outside the old 
IFU (IFU-2013)15 or the new, refined IFU (IFU-2016).14 Aneurysm diameter was measured as the 
maximum cross-sectional diameter on reconstructed slices perpendicular to the main aortic axis, 
measuring from adventitia to adventitia. Aneurysm growth was defined as a change of ≥5mm 
between the 1-month CT and subsequent scans.  
 
Patient management and follow-up imaging protocol 
EVAS was introduced in our institute in December 2013 under the supervision of our Techniques and 
Medical Devices group, with strict audit and reporting requirements. Informed consent was obtained 
for the procedure; this included an understanding that procedural outcomes would be evaluated 
and reported accordingly. Our follow-up protocol includes postoperative imaging by abdominal 
radiography on the first day; duplex ultrasound imaging and arterial-phase CT at 1 month; followed 
by yearly abdominal radiographs, duplex scans, and arterial-phase CT, except in patients with 
significant renal impairment who have uncomplicated 1-month CT appearances and favourable 
anatomical features, as judged by an experienced operator (RM). CT data were reconstructed using 
the thinnest available slice (≤2 mm) before review. 
 
Measurements10  
The use of a Picture Archiving and Communications System (PACS) built-in ‘vessel analysis’ module 
(Carestream software version 11.4.1.1011; Carestream Health Inc., Rochester, NY, USA) enabled the 
measurement of stent movement.  Each scan was loaded onto a PACS workstation to generate a 
semi-automated central luminal line (CLL) through each stent using the ‘Aorta Protocol’ tool in the 
vessel analysis software.  The ‘Aorta Protocol’ made switching from left stent to the right, and vice 
versa, automated and provided a more unified generation of the stent CLL. The CLL of each stent 
was checked by scrolling through all the anatomical planes available: axial, coronal and sagittal; 
ensuring that it was indeed traveling through the centre of the luminal space. A two-dimensional 
oblique axial view, perpendicular to the CLL, was used to determine the position of the stent graft 
against the specified reference vessel.  We defined this as the point most inferior of the superior 
mesenteric artery (SMA), where a clear separation of this vessel from the aortic wall was visible, 
seen on the first oblique axial CLL reformatted image. The distance between this point and the first 
oblique axial CLL reformat that contained at least two stent struts was measured, reducing the 
probability of mistaking calcification for the actual stent graft. Each CLL measurement was compared 
with the same measurement on the 1-year CT scan and, if available, subsequent scans. 
Measurement differences between the CT scan at 1 month and subsequent scans, for the same 
anatomic location, were used to determine whether device movement had occurred. Caudal 
movement was indicated by a positive value and cranial with a negative value. The bias (difference 
between true movement and the CT assessment), intra-observer and inter-observer variability when 
using this method for the movement definition of ≥4mm had been previously assessed.12 
 
Data Analysis 
SPSS version 22.0 (SPSS, Inc., Chicago, IL, USA) was used to analyse our data. Continuous variables 
were assessed for normality with the Kolmogorov–Smirnov test and presented as mean and 
standard deviation (SD) or median and range, according to the underlying distributions. Paired 
comparisons were performed with a t-test or Mann-Whitney U test. Kaplan-Meier survival curves 
were generated to visualise freedom from proximal displacement or migration patterns. The log rank 
test was used to compare proximal displacement or migration rates between different IFU groups. 
The Fisher’s Exact test was used to assess the association of aneurysm growth with proximal 
displacement or migration.   
Results  
112 consecutive patients (86 men) with a mean age of 77 (SD: 7) years underwent EVAS between 
December 2013 and January 2018. The following patients were excluded: seven who underwent 
EVAS to reline previously inserted grafts; eleven chimney-EVAS patients; six who had missing post-
operative scans due to loss to follow-up (2), death after 30 days but before 1 year (3) and severe 
renal impairment contra-indicating contrast CT (1); twelve who had not yet had their 1-year post-
operative scan and one patient who underwent EVAS for a ruptured aneurysm. 
 
Seventy-five patients (57 men) were included in this study with a mean age of 76 (SD: 7.6) years. All 
patients had a 1-year follow-up CT; forty-three had a 2-year post-EVAS CT; fifteen had a CT scan at 3-
years; and two had a CT at 4 years. Pre-operative anatomical data is displayed in Table 1. The 
anatomical features of 20 patients (26%) were within both IFU-2013 and IFU-2016; 55 (72%) patients 
were within IFU-2013; of these, 35 were outside the new IFU-2016; 20 patients were outside both 
IFU-2013 and IFU-2016. EVAS was performed using paired stents in all but three patients, who 
received an aortouni-iliac (AUI) device.  
 
There were no post-operative deaths but 19 patients (25%) experienced a complication within 30-
days, of whom seven required a secondary intervention (Table 2). There was one operative type Ia 
endoleak, which resolved at 48 hours. Over the 4-year period, forty-two patients had proximal 
displacement of ≥4mm in one or more stents. 25 were first detected within one year (33% of the 
point population of 75), 12 were detected at two-year follow-up (28% of the point population of 43) 
and a further five at 3-year follow-up (33% of the point population of 15). Sixteen patients had 
migration of >10mm: 5 were first detected at one year (7%); 6 at two years (14%); 4 at three years 
(27%) and one at 4 years (50%). There were no differences observed in the incidence of proximal 
displacement /migration between the left and right stents irrespective of the definition (Table 3). 
Figure 1 shows the evolution of proximal displacement and migration in time. 
 
Proximal displacement/migration was affected by compliance with IFU-2013 and IFU-2016, as 
summarized in Table 4. The highest incidence of proximal displacement (70% for a ≥4mm definition) 
was observed when the device was outside both IFUs; this reduced to 30% when the procedure was 
within the new IFU (IFU-2016). 
 
Outcomes beyond 30 days included 8 deaths, none aneurysm related. Three patients, all with 
evidence of proximal displacement or migration, demonstrated a type Ia endoleak during follow up. 
A total of ten patients underwent late re-intervention of whom six had at least 4mm of proximal 
displacement and five had migration of at least 10 mm. The details of the re-interventions and their 
relationship with proximal displacement or migration are summarised in Table 5.  
 
Figure 2 shows freedom from proximal displacement  and migration for the left stent, right stent and 
the whole cohort. Figure 3 shows freedom from proximal displacement and migration of each of the 
IFU groups. Proximal displacement was significantly more frequent among patients whose anatomy 
did not conform to any IFU (p=0.025). During follow-up, 14 patients displayed aneurysm growth 
≥5mm (median 5.5; range 5-15 mm). This was significantly associated with proximal displacement 
(p=0.03). In six patients proximal displacement preceded aneurysm growth, in three patients 
aneurysm growth preceded proximal displacement, in three patients proximal displacement and 
aneurysm growth were detected on the same scan; in two other patients, aneurysm growth was 
detected but there was no proximal displacement. 
 
 
 
 
 
 
 
 
 
 
 
 
 Discussion 
This study confirms that proximal stent displacement occurs in a significant proportion of patients 
who undergo EVAS and is associated with anatomy outside the current IFU.  Movement can be 
progressive, can affect one or both stents and is associated with aneurysm growth, a finding that 
had not been described before. 
We had previously reported, in a much smaller cohort of patients with shorter follow-up, the 
occurrence of post-EVAS stent proximal displacement, defined as and measured with the same 
criteria used in the present study.10 Migration and other types of stent displacement have also been 
described by other authors,6,7,8,16,17,18,19 although definition and measurement techniques have not 
been consistent in the literature. In contrast, Van den Ham et al. did not observe migration in patient 
cohorts with high adherence to IFU at one year20. 
We chose to use two definitions for stent displacement, one being the SVS definition for EVAR (>10 
mm), which is more than 15 years old11. We believe that this definition, whilst established in the 
literature, is outdated, partly because modern cross-sectional imaging allows the detection of much 
smaller stent movements, but also because of the inherent differences between EVAR and EVAS, 
which seals the aneurysm without active fixation at the landing zones (i.e. without radial force 
and/or hooks and barbs). As aortic necks are rarely perfectly cylindrical, even small post-EVAS stent 
movements may result in loss of contact between the endobags and the aorta (or between the two 
endobags), with consequent loss of seal and re-pressurization of the aneurysm.  For these reasons, 
we also reported proximal displacement according to a less conservative (≥4 mm) definition that we 
have previously used for fenestrated EVAR and EVAS11,21. Interestingly, IFU 2016 compliant patients 
displayed approximately half the incidence of proximal displacement of the rest of the patients, 
regardless of definition (≥4 mm or >10 mm).  
Whilst proximal stent displacement may be of particular relevance in short aortic necks, its potential 
clinical impact would also depend on the length of endobag/aorta apposition at the landing zones 
(the “seal”). In our experience, however, on CT scans, it is not always possible to measure length of 
seal, particularly in narrow necks, where the contour of endobags is difficult to define. We thus 
decided not to include this variable in the manuscript, as we were not confident on our ability to 
measure it reliably 
The incidence of proximal displacement we demonstrated should be interpreted in context, by 
comparing it to that of post standard EVAR, when this is measured with similar criteria. A recent 
systematic review demonstrated an 8.6 % incidence of post-EVAR proximal displacement (≥5 mm) at 
1-3 years; this was associated with poor anatomy and, unlike in our study, with type Ia endoleaks22. 
We also observed a significant incidence of aneurysm growth in our series, but only three late 
endoleaks. It is generally thought that aneurysm growth rarely occurs in absence of aneurysm 
perfusion and pressurisation. It is also accepted that aneurysm pressurisation post-EVAS can occur in 
absence of a visible endoleak23. Our findings thus suggest that even small degrees of proximal 
displacement may be clinically significant. It is possible that small movements may allow blood to 
seep between the endobags and the aorta, or between the two endobags, effectively creating a 
wedge-like communication between the proximal circulation and the aneurysm.  Even after 
thrombosis of such communication, aneurysm growth may occur, as thrombus is capable of 
transmitting pressure24. EVAS may thus behave differently from EVAR during follow up. Our group 
recently highlighted the potential effect of certain forces (such as gravity and vibration) on 
implanted Nellix prostheses25; these would not be expected to have the same effect post-EVAR, due 
to the difference in mass between traditional endografts and the Nellix prosthesis. Whilst it is still 
unclear whether such effects have significant clinical consequences, their observation underlines 
that post-treatment evolution of aneurysms treated by EVAS may be different from that of 
aneurysms treated by EVAR.  
Whilst it is logical to assume that aneurysm growth follows proximal displacement /migration, it is 
also theoretically possible that proximal displacement could be secondary to aneurysm growth, as 
such growth would create additional space for the stent/endobag complex to move into.  In support 
of this theory, we observed aneurysm growth before proximal displacement in three cases. 
Unfortunately, our study cannot establish whether aneurysm growth was a cause or a consequence 
of proximal displacement. Further research is necessary to clarify this relationship. 
Our findings confirm that there is a reduction in proximal displacement incidence when complying to 
the recently refined IFU, which was introduced after a higher than expected incidence of migration 
was observed in American pre-marketing studies26. However, proximal displacement rate in this 
group was still found to be at 30% despite adherence to the new IFU. Our results should encourage 
clinicians to pursue close surveillance even in patients treated within IFU for early detection of 
proximal displacement and AAA growth.  
This study has obvious limitations, as it was retrospective, limited to a single centre and to a 
relatively small population. Its strengths, however, include the prospective nature of clinical data 
collection, ensuring comprehensive capture of clinical adverse events, the low rate of loss to follow-
up for a retrospective study and the previously validated CT measurement techniques. It should 
encourage further research on post-EVAS follow up in order to fully understand the mechanisms 
that lead to treatment failure. 
Conclusion 
Infrarenal EVAS is prone to proximal displacement, particularly when performed outside IFU. This 
proximal displacement may cause aneurysm growth in absence of endoleaks. The definition of 
migration used for EVAR may be inappropriate for EVAS; a new consensus on definition and 
measurement technique is necessary. Clinicians should continue close surveillance post EVAS, 
particularly in patients treated outside IFU. 
 
Table 1. Pre-operative aortic anatomy.   
Anatomical feature All patients Patients 
outside IFU 
Aortic neck length (mm) 27 (6-65) 29(6-65) 
Infra-renal neck angulation (degrees) 34 (0-78)  32 (0-77) 
Maximum neck diameter (mm) 27 (5) 28(5) 
Maximum aortic lumen diameter (mm) 44 (14) 41 (14) 
Maximum aneurysm diameter (mm) 60 (54-93) 63(54-93) 
Aortic bifurcation diameter (mm)  28 (14-54) 30(15-54) 
Maximum right common iliac artery diameter (mm) 16 (4) 16(4) 
Maximum left common iliac artery diameter (mm) 16 (4) 16(4) 
Values are expressed as median (range) or mean (standard deviation). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. 30-day complications.  
Variable  n.(%) Details 
Complications 19(25) Device/Aneurysm related 
complications:  
1 contrast nephropathy 
5 Limb ischemia  
1 Left internal iliac coverage 
2 Access site haematoma  
2 AAA rupture (asymptomatic) 
1 intraoperative ruptured 
endobag 
1 Intraoperative stent balloon 
rupture 
1 intraoperative rupture of 
distal external iliac artery  
 
 
 
 
Other complications:  
2 Acute kidney Injury 
1 Paraparesis, acute 
coronary syndrome and 
neck of femur fracture 
2 Hospital acquired 
pneumonia 
 
Re-intervention 7(9) 1 evacuation of haematoma   
1 Insertion of spinal drain and 
hip hemiarthroplasty 
2 thrombectomy  
 
 
 
1 femorofemoral bypass + 
fasciotomies 
1 Angioplasty + stenting  
1 Embolectomy 
 
Endoleak 1(1) Type Ia, resolved within 48h  
Death 0 -  
 
Table 3. Incidence and extent of migration at any time. 
 Total 
patient 
number 
Migration  
n(%) 
Median migration 
(range)a (mm) 
  ≥4mm >10mm ≥4mm >10mm 
Left stent 73 31(42) 10(14) 7.6(4-30) 16(11-30) 
Right stent 74 34(46) 13(18) 7.3(4-29) 15(10.2-29) 
Per patient 75 42(56) 16(21) 7.5(4-30) 15(10.2-30) 
aamong patients with migration 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Distance between stent and superior mesenteric artery in patients with proximal 
displacement (1a and 1b) and migration (1c and 1d) over time. 
 
 
Table 4. Migration at any time in different IFU groups. 
 Proximal displacement n./N 
(%) 
Migration n./N (%) 
IFU-2016 compliant 6/20 (30) 2/20 (10) 
IFU-2016 non-compliant 36/55 (65) 14/55 (25) 
IFU-2013 compliant 
(Non-compliant with IFU-
2016) 
22/35 (63) 9/35 (26) 
Non-compliant with IFU-
2013 and IFU-2016 
14/20 (70) 5/20(25) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Late re-interventions. 
Follow-up range 12-48 months, median: 24 months 
                        Migrated cohort Non-Migrated cohort  
 ≥4mm (N=42) >10mm (N=16) (N=34) 
Variable n. Details n. Details n. Details 
Late Re-
intervention 
6 1 Conversion to 
open repair 
1 repeated EVAS,      
1 superficial 
femoral artery 
angioplasty  
1 Limb extension,  
1 Nellix-in Nellix 
ChEVAS      
1 Femoro-
femoral  bypass  
 
5 1 repeated EVAS,      
1 superficial femoral 
artery angioplasty  
1 Limb extension,  
1 NINA ChEVAS    
1 Cross-over bypass 
surgery    
4 1 femoral 
thrombectomy and 
embolectomy 
1 thrombectomy 
and Tibial bypass 
1 External Iliac 
artery stent  
1 tibial bypass 
 
Endoleak 3 Type 1a  2 Type 1a 0 - 
Late Death 5 not aneurysm 
related 
2 not aneurysm related 3 not aneurysm 
related 
ChEVAS: Chimney Endovascular aneurysm sealing: EVAS extending into the supra-renal segment using chimneys 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 2. Freedom from proximal displacement  (2a, 2b, 2c) and migration (2d, 2e, 2f)  
 
 
 
 
Figure 3. Freedom from proximal displacement (3a) and migration (3b) in different IFU groups. 
IFU-2016 compliant: dotted line; IFU-2013 compliant (Non-compliant with IFU-2016): line and dot 
line; Non-compliant with IFU-2013 and IFU-2016: continuous line. 
3a - Log rank (mantel cox) results: IFU- 2016 compliant vs Non-compliant with IFU-2013 and IFU-
2016: 0.037; IFU-2016 compliant vs IFU- 2013 compliant (Non-compliant with IFU-2016): 0.031; 
IFU-2016 compliant vs IFU-2016 noncompliant: 0.025; IFU-2013 compliant (Non-compliant with IFU-
2016) vs Non-compliant with IFU- 2013 and IFU-2016: 0.468. 
3b - Log rank (mantel cox) results: IFU-2016 compliant vs Non-compliant with IFU-2013 and IFU-
2016: 0.159; IFU-2016 compliant vs IFU-2013 compliant (Non-compliant with IFU-2016): 0.079; IFU-
2016 compliant vs IFU-2016 non-compliant: 0.076; IFU-2013 compliant (Non-compliant with IFU-
2016) vs Non-compliant with IFU-2013 and IFU-2016: 0.749. 
Standard errors for each group at specified points can be found in appendix 1. 
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